Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target

OA Sukocheva, H Furuya, ML Ng, M Friedemann… - Pharmacology & …, 2020 - Elsevier
Inflammatory gastrointestinal (GI) diseases and malignancies are associated with growing
morbidity and cancer-related mortality worldwide. GI tumor and inflammatory cells contain …

Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances

S Pyne, DR Adams, NJ Pyne - Progress in lipid research, 2016 - Elsevier
Sphingosine kinases (isoforms SK1 and SK2) catalyse the formation of a bioactive lipid,
sphingosine 1-phosphate (S1P). S1P is a well-established ligand of a family of five S1P …

Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes

Y Zhong, K Lee, Y Deng, Y Ma, Y Chen, X Li… - Nature …, 2019 - nature.com
Arctigenin (ATG) is a major component of Fructus Arctii, a traditional herbal remedy that
reduced proteinuria in diabetic patients. However, whether ATG specifically provides …

[HTML][HTML] The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance

PP Ruvolo - BBA clinical, 2016 - Elsevier
Aberrant activation of signal transduction pathways can transform a normal cell to a
malignant one and can impart survival properties that render cancer cells resistant to …

[HTML][HTML] The emerging role of FTY720 (Fingolimod) in cancer treatment

C White, H Alshaker, C Cooper, M Winkler… - Oncotarget, 2016 - ncbi.nlm.nih.gov
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple
sclerosis that sequesters T-cells to lymph nodes through functional antagonism of …

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer

O Kauko, J Westermarck - The international journal of biochemistry & cell …, 2018 - Elsevier
Propagation of transient signals requires coordinated suppression of antagonistic
phosphatase activity. Protein phosphatase 2A (PP2A) is a broad specificity serine/threonine …

[HTML][HTML] Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

AR Clark, M Ohlmeyer - Pharmacology & therapeutics, 2019 - Elsevier
Abstract Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that
catalyzes the selective removal of phosphate groups from protein serine and threonine …

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer

AS Farrell, B Allen-Petersen, CJ Daniel, X Wang… - Molecular Cancer …, 2014 - AACR
Pancreatic cancer is a deadly disease that is usually diagnosed in the advanced stages
when few effective therapies are available. Given the aggressive clinical course of this …

Targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment

AH Janneh, B Ogretmen - Cancers, 2022 - mdpi.com
Simple Summary Sphingolipids, which are important cell membrane components, have
critical roles in regulating cancer cell signaling to control pro-tumoral or antitumoral …

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

I Peris, S Romero-Murillo… - Blood, The Journal …, 2023 - ashpublications.org
Venetoclax combination therapies are becoming the standard of care in acute myeloid
leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is …